This study looks at how well two treatments work for patients with multiple myeloma (MM), a type of blood cancer, after they have had a special procedure called autologous stem cell transplantation (ASCT). Patients will take either a drug called Lenalidomide alone or with another drug called Daratumumab/rHuPH20. After 2 years of treatment, a test called MRD (Minimal Residual Disease) will check if there are any cancer cells left. If MRD is positive, treatment continues; if negative, patients may stop treatment. This study can last up to 7 years, with follow-up for up to 15 years.

• Study Duration: Up to 7 years of treatment and follow-up for 15 years.
• Treatment: Possible use of Lenalidomide alone or with Daratumumab/rHuPH20.
• Eligibility: Must have MM and have undergone ASCT.